WEST PHARMACEUTICAL SERVICES INC
NYSE: WST·Exton, Pennsylvania·CIK 0000105770
- Price
- $417.80
- Base IV
- $120.66
Valuation snapshot
At $417.80, the price is above even our bull case of $164.43.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $120.66
- 29% of the price · range $81.13–$164.43
- Price vs base case
- 246% above
- $417.80 against $120.66
- Base case · our researched forecast, 2026-11-13See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $81.13 to bull $164.43. Values per share.
Price against each value
- Bear case
- $81.13
- Price 415% above
- No growth
- …
- —
- Base case
- $120.66
- Price 246% above
What does West Pharmaceutical Services do?
West Pharmaceutical Services designs and manufactures primary packaging, containment systems, and drug delivery devices for pharmaceutical and medical device companies to ensure safe drug storage and administration.
It brought in $3.4B of sales in the 12 months to Sep 2026.
Led by Michel Lagarde, President and Chief Executive Officer since 2026. West Pharmaceutical Services Form 8-K (Item 5.02) – Appointment of Michel Lagarde as President and CEO
- Industry
- Healthcare
- Based in
- Exton, Pennsylvania
- Trades on
- NYSE as WST
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 19¢ was left as profit after every cost, interest and tax. The biggest cost is running the business, 77¢ of every dollar.
- Running the business77¢
- Tax5¢
- Left as profit19¢
- Other items after tax came back in+1¢
Who pays West Pharmaceutical Services, and for what?
West makes packaging, containers, and delivery devices used with injectable medicines, along with related testing and support services. It also designs and manufactures complex medical and other devices for customers, earning revenue from sales of products and services.
Its customers are pharmaceutical, biotechnology, generic drug, diagnostic, and medical device companies.
Proprietary Products
81%Proprietary packaging and drug containment products, delivery devices, integrated systems, and laboratory and technical services.
West NovaPure elastomeric vial stoppersImage: West Pharmaceutical Services Contract-Manufactured Products
19%Design, manufacture, and automated assembly of customer devices and components, including for pharmaceutical, diagnostic, and medical device uses.
Cleanroom contract manufacturingImage: West Pharmaceutical Services
Where its work physically happens, beyond headquarters:
- Eschweiler plant — Eschweiler, Germany. West's largest manufacturing plant produces elastomer components for injectable medicines and is one of its high-value packaging component centers of excellence.
- Damastown facility — Dublin, Ireland. A 165,000-square-foot expansion adds commercial-scale drug handling and automation capacity for high-volume injectable therapies, including GLP-1 treatments.
- Grand Rapids facility — Grand Rapids, United States. West identifies this contract manufacturing facility as a site for GLP-1 drug-delivery device production.
- Kinston plant — Kinston, United States. Its elastomer production supports injectable-drug packaging, and West designates it a high-value packaging component center of excellence.
- Jurong plant — Jurong, Singapore. This high-value packaging component center of excellence provides regional production capacity for West's Asia-Pacific customers.
How is the business doing?
Sales grew from $2.1B in 2020 to $3.1B in 2025, about 7% a year.
Running the business leaves about 23¢ of each sales dollar as operating profit, up from 19¢ in 2020.
After paying for its upkeep and new investment, it had $453.4M of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
West says it exists to contain and deliver injectable therapies that improve patients’ lives.
“We contain and deliver injectable therapies that improve patient lives.”
Who is responsible for the plan?
- Michel LagardePresident and Chief Executive Officer
Leads West Pharmaceutical Services as President and Chief Executive Officer and serves on its Board of Directors. The CEO oversees the whole company, including its Proprietary Products segment and its Contract-Manufactured Products segment.
- Shane A. CampbellSenior Vice President, Chief Proprietary Segment Officer
Oversees West's Proprietary Products segment. The Proprietary Products segment sells West's own containment and drug-delivery components and systems to pharmaceutical and biotech customers.
Roles checked November 13, 2026.
What management says it is working on now:
Grow high-value components
Management cited continued strength in biologics, customer upgrades to higher-value components, and growth in GLP-1 related components as drivers of recent results.
West Reports Second-Quarter 2026 ResultsExpand drug handling solutions
Management described a plan to add more steps for customers, including checking and installing drug cartridges into delivery devices, with the business expected to build over time.
West Pharmaceutical Services Q2 2026 Earnings Call TranscriptInvest in capacity and automation
Management said it is investing to support organic growth, with particular emphasis on high-value products and finishing processes.
West Pharmaceutical Services Q2 2026 Earnings Call TranscriptMaintain product quality and regulatory readiness
The company says quality, manufacturing expertise, and regulatory compliance are central to serving customers and delivering products reliably.
2025 Form 10-K
- 2026 organic net sales growth, 2026
- 10% to 11%
- West Pharmaceutical Services Q2 2026 Earnings Call Transcript
- Annex 1 related product mix shift, 2026
- 200 basis points of revenue growth
- West Pharmaceutical Services Q2 2026 Earnings Call Transcript
What's changing right now?
Growth is slowing. In Q3 2026 it sold 9% more than a year earlier. The year before, quarters averaged 13%.
Its operating margin is wider than a year ago: 31¢ per sales dollar, against 21¢.
The share price is about where it was in Oct 2026, near $417.80.
Recently
October 29, 2026
Adjusted operating margin, quarterly changed to 25.3%
WST Q3 2026 earnings releaseOctober 29, 2026
Full-year capital expenditure guidance changed to $217.5M
WST Q3 2026 earnings releaseOctober 29, 2026
Net sales growth YoY, quarterly changed to 8.7%
WST Q3 2026 earnings release
Coming up
Late 2026 into 2027
Drug handling solutions ramp
Management said revenue from its drug handling solutions program is expected to build toward the end of 2026 and ramp further into 2027.
West Pharmaceutical Services Q2 2026 Earnings Call Transcript2027
Daikyo license agreements
The company says certain important product and process licenses expire in 2027; renewal or early termination could affect access to those technologies.
2025 Form 10-K
Our own estimate moved too: the base case went from $116.16 to $120.66 a share between our last two valuations. The biggest reason: Net sales growth YoY, quarterly moved from an unreported prior value to 8.7%, as reported in WST Q3 2026 earnings release.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Dependence on injectable medicines
If customers shift to medicines taken by other routes or to treatments requiring fewer injections, demand for West’s packaging and delivery products could fall.
From the company's own filingsWould hit how fast sales grow2025 Form 10-K
Customer concentration
The ten largest customers generated 47.6% of 2025 sales, and one customer accounted for 15.8%. A loss of a major customer or fewer orders could materially affect results.
From the company's own filingsWould hit how fast sales grow2025 Form 10-K
Supply interruptions and input costs
Some important raw materials come from single suppliers, and prices for materials and energy can change. Shortages or costs West cannot pass on to customers could disrupt production or reduce profits.
From the company's own filingsWould hit how much of each sale it keeps2025 Form 10-K
Manufacturing disruption
Damage, outages, quality problems, or other events could interrupt production, especially where a product is made at only a few sites, and affect sales and customer relationships.
From the company's own filingsWould hit how fast sales grow2025 Form 10-K
Competition and pricing pressure
Customers and competitors put pressure on prices. If West cannot offset this through its services, efficiency, or lower costs, its sales or profitability may suffer.
From the company's own filingsWould hit how much of each sale it keeps2025 Form 10-K
Product approvals and development
New products can take years to develop and may need regulatory approval and customer acceptance. Delays or failure to commercialize them could limit future sales.
From the company's own filingsWould hit how fast sales grow2025 Form 10-K
Management said Q4 could be lumpy and implied only 6–7% organic growth.
From our researchWould hit how fast sales growWST Q3 2026 earnings call transcript
Operating margin was only 15.3% in Q1 2025 and 19.5% in Q4 2025 (supplied actuals), so 25% has been sustained only briefly.
From our researchWould hit how much of each sale it keepsWST Q1 2026 earnings release
Is it a good business?
From 2016 to 2025 it earned between 14% and 34% on the capital invested in it, a median of 19%. Its cost of capital in the latest valuation is 9.8%; returns were above it in every one of the 10 years.
From 2016 to 2025 it earned between 12% and 28% on its shareholders' equity, a median of 17%.
Over 10 years its operating margin ranged from 13¢ to 27¢ per sales dollar, a median of 19¢. Gross margin ran from 32¢ to 42¢.
Cost of capital 9.8%
It bought back shares: the count fell 2.5% in a year, so each remaining share owns a slightly bigger slice.
It holds $252.3M more in cash than it owes.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $417.80. Our put its value between $81.13 and $164.43, with $120.66 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $81.13
This scenario assumes West's sales boom of 2026 fades quickly and the business returns to slow growth of a few percent a year, with profits slipping back toward 2025 levels after the sale of one product line.
Base case, $120.66
This scenario assumes West keeps growing at a healthy mid-to-high single-digit pace after a very strong 2026, while holding on to most of its recent gains in profitability as higher-value drug packaging becomes a bigger share of sales.
Bull case, $164.43
This scenario assumes the strong demand that pushed West's sales up by double digits in 2026 lasts for several more years, and that its shift toward premium drug-packaging products keeps lifting profitability above anything it has earned before.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects far more than we do.Price above value: 246%
For West Pharmaceutical Services to be worth today's $417.80, sales would need to grow about 39.2% a year. We assume 5.9%. Over the last 5 years, sales grew 4.8% a year.
Or, if sales grow 5.9% as we assume, the price works with a profit margin of 88.4% (we assume 25.0%).
Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.
Do you think sales can grow 39.2% a year?
Try your own numbersWe're moderately sure of this range: it scores 66 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $120.66 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average5.9%
- Operating margin25.0%
- Long-term growth rate3.0%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$120.66 -71.1%


